According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 50.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on MyoKardia Inc is a Strong Buy with an average price target of $82.50, a 42.5% upside from current levels. In a report issued on October 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $90 price target.
Based on MyoKardia Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.79 million. In comparison, last year the company had a GAAP net loss of $14.17 million.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.